Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody-Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis.

Cancers (Basel) · 2022 · PMC9321046 · PMID 35884431

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Additionally, T-DXd showed a clear trend in favoring PFS compared with afatinib monotherapy (HR, 0.14; 95% CrI, 0.02–1.00), although it did not reach significance.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.